Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Mauriac

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Expression profiling in breast carcinoma: new insights on old prognostic factors?Marc Debled, Gaëtan MacGrogan, Isabelle de Mascarel, et al.
Critical Reviews in Oncology/Hematology|November 2, 2010
First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysisMarc Debled, Nicolas Madranges, Cécile Mertens, et al.
British Journal of Cancer|November 15, 2007
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysisM Debled, N Houédé, N Madranges, et al.
Oncology|November 27, 2009
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?Marc Debled, Nicolas Madranges, Alexandra Trainaud, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 30, 2008
D2-40 in breast cancer: should we detect more vascular emboli?Isabelle de Mascarel, Gaëtan MacGrogan, Marc Debled, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 9, 2008
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendationsFrédéric Chibon, Isabelle de Mascarel, Ghislaine Sierankowski, et al.
Cancer Treatment Reviews|October 4, 2005
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use ProgrammeGuenther G Steger, Maya Gips, Sergio D Simon, et al.
American Journal of Surgery|May 13, 2014
Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision makingMarc Debled, Gaël Auxepaules, Christine Tunon de Lara, et al.
Virchows Archiv : an International Journal of Pathology|June 7, 2007
Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-upIsabelle de Mascarel, Gaëtan MacGrogan, Simone Mathoulin-Pélissier, et al.
Cancer|June 22, 2010
Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?Florence Ragage, Marc Debled, Gaëtan MacGrogan, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2007
Expression profiling in breast carcinoma: new insights on old prognostic factors?Marc Debled, Gaëtan MacGrogan, Isabelle de Mascarel, et al.
Critical Reviews in Oncology/Hematology|November 2, 2010
First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysisMarc Debled, Nicolas Madranges, Cécile Mertens, et al.
British Journal of Cancer|November 15, 2007
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysisM Debled, N Houédé, N Madranges, et al.
Oncology|November 27, 2009
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?Marc Debled, Nicolas Madranges, Alexandra Trainaud, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 30, 2008
D2-40 in breast cancer: should we detect more vascular emboli?Isabelle de Mascarel, Gaëtan MacGrogan, Marc Debled, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 9, 2008
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendationsFrédéric Chibon, Isabelle de Mascarel, Ghislaine Sierankowski, et al.
Cancer Treatment Reviews|October 4, 2005
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use ProgrammeGuenther G Steger, Maya Gips, Sergio D Simon, et al.
American Journal of Surgery|May 13, 2014
Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision makingMarc Debled, Gaël Auxepaules, Christine Tunon de Lara, et al.
Virchows Archiv : an International Journal of Pathology|June 7, 2007
Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-upIsabelle de Mascarel, Gaëtan MacGrogan, Simone Mathoulin-Pélissier, et al.
Cancer|June 22, 2010
Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?Florence Ragage, Marc Debled, Gaëtan MacGrogan, et al.
Pageof 6